Elecsys hs ctnt assay

Manufactured by Roche

Sourced in Switzerland

The Elecsys hs-cTnT assay is an in vitro diagnostic test used to measure the concentration of high-sensitivity cardiac troponin T (hs-cTnT) in human blood samples. It is designed to aid in the diagnosis and management of myocardial infarction and other cardiovascular conditions.

Automatically generated - may contain errors

Lab products found in correlation

Cobas e601 module, by Roche (1 mentions)

6 protocols using elecsys hs ctnt assay

Cardiac Biomarkers for Anthracycline Toxicity

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cardiac Troponin T was selected based on its sensitivity in detecting acute cardiac damage, and is validated as a biomarker for anthracycline-related cardiotoxicity [8 (link)]. NT-pro-BNP is a biomarker for long-term cardiac remodelling, secreted by cardiomyocytes in response to cardiac wall stress [37 (link)]. Plasma cTnT and NT-pro-BNP were analysed by the clinical laboratory at Karolinska University Hospital using electrochemiluminescense immunoassay, ECLIA. The high-sensitivity cardiac troponin T (hs-cTnT) assay (Elecsys hs-cTnT assay Roche Diagnostics, Mannheim, Germany) has a limit of detection (LoD) of 5 ng/l, a 99th percentile value of 14 ng/l and a coefficient of variance (CV) of 10% at 13 ng/l.

Ansund J., Mijwel S., Bolam K.A., Altena R., Wengström Y., Rullman E, & Rundqvist H. (2021). High intensity exercise during breast cancer chemotherapy - effects on long-term myocardial damage and physical capacity - data from the OptiTrain RCT. Cardio-oncology, 7, 7.

+ Open protocol

+ Expand

Evaluating Cardiac Troponin Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols

Testing was undertaken using both commercially available hs-cTn (T and I) assays. One study (TRUST) used the Elecsys hs-cTnT assay (Roche, Basel, Switzerland) and one study (EDACS-ADP) used the Architect hs-cTnI assay (Abbott Diagnostics, Chicago, Illinois, USA) in routine clinical care (online supplementary table 2), where analysis was undertaken in real time. In remaining studies, research samples taken on presentation were centrifuged and serum stored frozen at ≤−70°C for later analysis. The LoD for hs-cTnT is 5 ng/L.17 (link) For hs-cTnI, a range of 1.2–1.9 ng/L for the LoD is quoted,17 (link) we rounded this value to 2 ng/L as is common laboratory practice.18 Prior analysis of applying the LoD at 2 ng/L, rather than 1.2 ng/L, for hs-cTnI, has demonstrated an improved efficacy (patients eligible for early discharge; 25.6% vs 18.8%) but with a reduction in diagnostic sensitivity (99.0% vs 97.9%).7 (link)

Carlton E.W., Pickering J.W., Greenslade J., Cullen L., Than M., Kendall J., Body R., Parsonage W.A., Khattab A, & Greaves K. (2017). Assessment of the 2016 National Institute for Health and Care Excellence high-sensitivity troponin rule-out strategy. Heart, 104(8), 665-672.

+ Open protocol

+ Expand

Comparison of Cardiac Biomarkers in Surgery

Check if the same lab product or an alternative is used in the 5 most similar protocols

The Elecsys hs-cTnT assay (Roche, Indianapolis, Ind), which is guideline compliant (American College of Cardiology/European Society of Cardiology and National Academy of Clinical Biochemistry/American Association for Clinical Chemistry), was introduced in July 2010. This test has a limit of detection of 3 pg/mL. The 99th percentile URL of this assay is 14 pg/mL. 11 Preoperative and postoperative troponin assay used at our hospital was the same hs-cTnT.
The CK-MB was assayed with an enzymatic assay (Elecsys; Roche), with a measuring range of 0.1 to 5 mg/dL, defined by the lower detection limit and the maximum of the master curve. A normal value at our laboratory was defined as <5 mg/dL. 12

Cubero-Gallego H., Lorenzo M., Heredia M., Gómez I, & Tamayo E. (2017). Diagnosis of perioperative myocardial infarction after heart valve surgery with new cut-off point of high-sensitivity troponin T and new electrocardiogram or echocardiogram changes. The Journal of thoracic and cardiovascular surgery, 154(3).

+ Open protocol

+ Expand

Biomarker Measurement Protocols for Acute Cardiac Injury

Check if the same lab product or an alternative is used in the 5 most similar protocols

In addition to routine clinical tests, study samples were collected at presentation. EDTA and lithium heparin plasma were separated and frozen at −80 °C, within 2 h of sampling for later analysis using hs-cTnI and hs-cTnT, and updated H-FABP assays, respectively. Hs-cTnI concentrations were measured on the ARCHITECT STAT platform (Abbott Laboratories, Abbott Park, Illinois). The assay has a limit of detection (LoD) of 2 ng/L, 99th percentile among healthy subjects of 26 ng/L, and sex-specific 99th percentiles of 34 ng/L for men and 16 ng/L for women. Hs-cTnT concentrations were measured with the Roche Elecsys hs-cTnT assay (Roche Diagnostics Limited, Switzerland). The hs-cTnT assay has a LoD of 5 ng/L and a 99th percentile of the upper reference limit of 14 ng/L. H-FABP concentrations were measured with an immunoturbidimetric H-FABP assay (Randox Laboratories Limited, United Kingdom) on the ARCHITECT platform. The H-FABP assay can be performed concurrently with hs-cTnI and hs-cTnT assays on the same sample, and requires 20 min from the time of blood sampling to obtain a value. The 99th percentile of H-FABP assay in a healthy reference population is 3.6 ng/mL and LoD of 0.75 ng/mL [16 (link)]. No sex-specific differences in the 99th percentile concentrations of H-FABP have been shown [16 (link)].

Young J.M., Pickering J.W., George P.M., Aldous S.J., Wallace J., Frampton C.M., Troughton R.W., Richards M.A., Greenslade J.H., Cullen L, & Than M.P. (2016). Heart Fatty Acid Binding Protein and cardiac troponin: development of an optimal rule-out strategy for acute myocardial infarction. BMC Emergency Medicine, 16(1), 34.

+ Open protocol

+ Expand

hs-cTnT Quantification in STOP-CP Study

Check if the same lab product or an alternative is used in the 5 most similar protocols

The hs-cTnT was quantified for the parent study (STOP-CP) at the University of Maryland School of Medicine using freshly first-thawed aliquots with the Roche Elecsys hs-cTnT assay (Roche Diagnostics; Basel, Switzerland). The assay had a range of 3–10 000 ng/L, a limit of quantification at 6 ng/L, and a CV <10%.^{27 (link)} We used the hs-cTnT result from the blood sample collected at ED arrival in STOP-CP. An hs-cTnT cut-off point at the 99th percentile URL (19 ng/L) was used for modelling purposes.

Ashburn N.P., Snavely A.C., Allen B.R., Christenson R.H., Herrington D.M., Hiestand B.C., Miller C.D., Stopyra J.P, & Mahler S.A. (2021). Monocyte chemoattractant protein-1 is not predictive of cardiac events in patients with non-low-risk chest pain. Emergency medicine journal : EMJ, 39(11), 853-858.

+ Open protocol

+ Expand

High-sensitivity Cardiac Troponin T Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum samples were obtained from arterial blood collected from the radial or femoral sheath on admission to the catheterization laboratory (immediately prior to PPCI) as well as from venous blood samples collected 12 hours post-PPCI. Cardiac troponin T was quantified with the Roche Elecsys hs-cTnT assay on the Cobas e601 module (Roche Diagnostics, United Kingdom).
According to manufacturer information, the hs-cTnT assay has a limit of detection reported at 2.05 ng/L and coefficient of variation <10% at the 99 th percentile (14 ng/L).

Coelho-Lima J., Georgiopoulos G., Ahmed J., Adil S.E.R., Gaskin D., Bakogiannis C., Sopova K., Ahmed F., Ahmed H., Spray L., Richardson G., Bagnall A.J., Stellos K., Stamatelopoulos K, & Spyridopoulos I. (2021). Prognostic value of admission high-sensitivity troponin in patients with ST-elevation myocardial infarction. Heart (British Cardiac Society), 107(23).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!